Control of dumping symptoms by somatostatin analogue in patients after gastric surgery.

Octreotide acetate is a long-acting analogue of the naturally occurring inhibitory gastrointestinal peptide, somatostatin. We tested the efficacy of octreotide in controlling the symptoms of dumping syndrome in response to a provocative meal in a randomized, double-blinded, crossover trial in nine severely affected patients. Pretreatment with octreotide acetate (100 micrograms injected subcutaneously) reduced postprandial dumping symptoms from a mean +/- SEM score of 15.7 +/- 1.6 (placebo treatment day) to 4.6 +/- 1.7. With placebo treatment, all nine patients became symptomatic in response to the meal, whereas with octreotide treatment, symptoms occurred in only two of nine patients. Similarly, all placebo-treated patients showed a postprandial increase in pulse rate to a mean +/- SEM of 105 +/- 6 beats per minute, whereas only one of nine octreotide-treated patients showed an increase in pulse rate (mean +/- SEM, 80 +/- 3 beats per minute). These differences were also statistically significant. While no significant changes were observed in postprandial hematocrit values or osmolality between placebo and octreotide treatments, octreotide prevented hypoglycemia in four affected patients and significantly inhibited insulin release. We conclude that octreotide is a useful tool in the treatment of patients with severe, refractory dumping syndrome.

[1]  N. Abumrad,et al.  Efficacy of Octreotide Acetate in Treatment of Severe Postgastrectomy Dumping Syndrome , 1990, Annals of surgery.

[2]  H. Körber,et al.  Extracellular space, blood volume, and the early dumping syndrome after total gastrectomy. , 1990, Gastroenterology.

[3]  J. Primrose.  Octreotide in the treatment of the dumping syndrome. , 1990, Digestion.

[4]  J. Sawyers.  Management of postgastrectomy syndromes. , 1990, American journal of surgery.

[5]  R. Landgraf,et al.  Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration. , 1989, Gastroenterology.

[6]  D. Johnston,et al.  Somatostatin analogue SMS 201–995 (octreotide) as a possible solution to the dumping syndrome after gastrectomy or vagotomy , 1989, British Journal of Surgery.

[7]  C. Lamers,et al.  Treatment of the Dumping Syndrome with the Somatostatin Analogue SMS 201–995 , 1988, Annals of Surgery.

[8]  Z. Tulassay,et al.  Benefit of somatostatin in dumping syndrome. , 1988, Surgery.

[9]  S. Mulvihill,et al.  The use of somatostatin and its analogs in the treatment of surgical disorders. , 1986, Surgery.

[10]  P. Reasbeck,et al.  The effect of somatostatin on dumping after gastric surgery: a preliminary report. , 1986, Surgery.

[11]  T. Adrian,et al.  Somatostatin and the dumping syndrome. , 1985, British medical journal.

[12]  F. Sundler,et al.  Continuous infusion of somatostatin evokes escape of gastric acid inhibition in the rat. , 1984, Gastroenterology.

[13]  S. Bloom,et al.  Gut hormone profile and gastric emptying in the dumping syndrome. A hypothesis concerning the pathogenesis. , 1983, Scandinavian Journal of Gastroenterology.

[14]  P. Raskin,et al.  Effect of intravenous somatostatin on jejunal absorption of glucose, amino acids, water, and electrolytes , 1980 .

[15]  M. Hobsley,et al.  The relationship between the rate of gastric emptying and the dumping syndrome , 1978, The British journal of surgery.

[16]  I. L. Herrington,et al.  Superiority of Antiperistaltic jejunal Segments in Management of Severe Dumping Syndrome , 1973, Annals of surgery.

[17]  H. Sigstad.  A clinical diagnostic index in the diagnosis of the dumping syndrome. Changes in plasma volume and blood sugar after a test meal. , 2009, Acta medica Scandinavica.